The short version of vaccine adjuvant fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-11 and is reviewed periodically as new material appears.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
=== Other === Overactive TGF-β pathway, with an increase of TGF-β2, was reported in the studies of patients with keratoconus. There is substantial evidence in animal and some human studies that TGF-β in breast milk may be a key immunoregulatory factor in the development of infant immune response, moderating the risk of atopic disease or autoimmunity. Skin aging is caused in part by TGF-β, which reduces the subcutaneous fat that gives skin a pleasant appearance and texture. TGF-β does this by blocking the conversion of dermal fibroblasts into fat cells; with fewer fat cells underneath to provide support, the skin becomes saggy and wrinkled. Subcutaneous fat also produces cathelicidin, which is a peptide that fights bacterial infections.
Gopsill, Frank Peter; Sexton, Brian (2006) [2001]. "Le natura, si – un schema, no". Historia de interlingua (in Interlingua). Archived from the original on 2022-04-12. Retrieved 2025-01-14. Hill-Meyer, Tobi; Scarborough, Dean (2014). "Sexuality". In Erickson-Schroth, Laura (ed.). Trans Bodies, Trans Selves: A Resource for the Transgender Community (1st ed.). Oxford UP. ISBN 978-0-19-932535-1. OCLC 944726648. Houglum, Peggy A.; Bertoli, Dolores B. (2012). Brunnstrom's Clinical Kinesiology. F. A. Davis Company. ISBN 978-0-8036-2352-1. Janeway CA, Travers P, Walport M (2001). "Effector mechanisms in allergic reactions". Immunobiology (5th ed.). Garland Science. Janeway CA (2005). Immunobiology (6th ed.). Garland Science. ISBN 0-443-07310-4. Kendall, Florence Peterson; et al. (2005). Muscles : testing and function with posture and pain (5th ed.). Baltimore, MD: Lippincott Williams & Wilkins. ISBN 0-7817-4780-5. Knight, Sarah; Tilg, Stefan, eds. (2015). The Oxford Handbook of Neo-Latin. New York: Oxford University Press. ISBN 978-0-19-088699-8. OL 28648475M. Krishnaswamy G, Ajitawi O, Chi DS (2006). "The human mast cell: an overview". Mast Cells. Methods in Molecular Biology. Vol. 315. pp. 13–34. doi:10.1385/1-59259-967-2:013. ISBN 1-59259-967-2. PMID 16110146. McArthur, Tom (ed.): The Oxford Companion to the English Language, (Oxford University Press, 1992). ISBN 0-19-214183-X Murphy K, Weaver C (2016). Immunobiology (9 ed.). Garland Science. ISBN 978-0-8153-4505-3.
== History == EAS was founded in Pacific Grove, Monterey County, California in 1992 by biochemist Anthony Almada, and businessman Ed Byrd. In 2012, Byrd founded EAB Lab. After discovering the possible benefits for athletes of creatine monohydrate supplementation, in December 1992 they acquired a kilogram of creatine and began trials. In 1993, they released the first commercially available creatine supplement intended specifically for strength and muscle enhancement under the EAS brand name Phosphagain. The product caught the eye of Bill Phillips, publisher of Muscle Media 2000 (usually referred to as "MM2K"), and he began to write about its benefits in the Natural Supplement Review and his subscriber-based newsletters. In 1994 he purchased EAS from Almada and Byrd, and was 100% owner of EAS until the sale to North Castle Partners. Phillips' subscriber base was the platform in which to tout his new acquisition. He promoted the company's products through heavy editorial-style advertisements in MM2K. Led by products like Myoplex Protein Supplement, Phosphagen and HMB, this eventually made EAS significant in the nutritional supplement industry. In 1999, North Castle Partners purchased EAS for $160 million. Phillips retained about a third of the company, which he sold in 2004. In 2005, EAS was purchased by Abbott Laboratories for approximately $320 million in a cash-for-stock transaction and existed as a solely-owned division of Abbott. The refreshed product line focused on sports bars, drink mixes, and similar products.
Continuing Arab disquiet over Allied intentions also led during 1918 to the British Declaration to the Seven and the Anglo-French Declaration, the latter promising "the complete and final liberation of the peoples who have for so long been oppressed by the Turks, and the setting up of national governments and administrations deriving their authority from the free exercise of the initiative and choice of the indigenous populations". In 1919, King Hussein refused to ratify the Treaty of Versailles. After February 1920, the British ceased to pay subsidy to him. In August 1920, five days after the signing of the Treaty of Sèvres, which formally recognized the Kingdom of Hejaz, Curzon asked Cairo to procure Hussein's signature to both treaties and agreed to make a payment of £30,000 conditional on signature. Hussein declined and in 1921, stated that he could not be expected to "affix his name to a document assigning Palestine to the Zionists and Syria to foreigners." Following the 1921 Cairo Conference, Lawrence was sent to try and obtain the King's signature to a treaty as well as to Versailles and Sèvres, a £60,000 annual subsidy being proposed; this attempt also failed. During 1923, the British made one further attempt to settle outstanding issues with Hussein and once again, the attempt foundered, Hussein continued in his refusal to recognize the Balfour Declaration or any of the Mandates that he perceived as being his domain.
Like most alchemical terms, the word "Sulfur" came to mean a lot of different things in alchemical works beyond its standard definition, representing concepts such as the active, masculine or fixing principle, combustion, or the soul. There were multiple "sulfurs", as the word was used as a Deckname, a secret codename for other substances.
Sources: en.wikipedia.org
Bin Laden's 1996 fatwa, in addition to similar statements that called for the killing of Americans, are seen by investigators as evidence of his motivation for the attacks. In a second fatwa in 1998, he outlined more of his objections to American foreign policy, such as American support of Israel and the U.S. and other nations' sanctions against Iraq, condemning the "protracted blockade." He claimed that the U.S. was being directed by an international Jewish conspiracy into killing as many Muslims as possible, and that all Muslims must wage a defensive war against the U.S. This was to be done until the aggression against them ceased. Bin Laden further claimed it would send a message to the American people, forcing the U.S. to reevaluate its policies. In a 1998 interview with American journalist John Miller, he stated:
Teva and Sandoz are by far the largest generics companies. They differ from their competitors not only in sales revenues but also because they are backwards integrated and have proprietary drugs in their portfolios. They also vie for the biosimilars market. Several thousand small or virtual pharma companies focus on R&D of just a few lead compounds. They typically originate mostly from academia. Therefore, their R&D strategy is more focused on the elucidation of the biological roots of diseases rather than developing synthesis methods.
The κ-opioid receptor or kappa opioid receptor, abbreviated KOR or KOP for its ligand ketazocine, is a G protein-coupled receptor that is encoded by the OPRK1 gene in humans. The KOR is coupled to the G protein Gi/G0 and is among related receptors that bind opioid-like compounds in the brain and are responsible for mediating the effects of these compounds. These include altering nociception, mood, reward system, and motor control. KOR is one of the two opioid receptors that bind dynorphin opioid peptides as the primary endogenous ligands, the other being newly deorphanized GPR139 receptor. In addition, oxytocin was found to be a positive allosteric modulator of KOR, and a variety of natural alkaloids, terpenoids, and synthetic ligands bind to the receptor. Dysregulation of this receptor system has been implicated in multiple psychiatric disorders including: depressive and anxiety disorders, disorders of diminished motivation, schizophrenia, borderline personality disorder, bipolar disorder, and substance use disorder. Ligands binding to the receptor have been approved to treat pruritus and manage pain. Aside from those indications they are investigated for various psychiatric disorders, irritable bowel syndrome, and acute stroke.
=== Developments in production === Until the end of the 19th century, vaccination was performed either directly with vaccine produced on the skin of calves or, particularly in England, with vaccine obtained from the calf but then maintained by arm-to-arm transfer; initially in both cases vaccine could be dried on ivory points for short-term storage or transport but increasing use was made of glass capillary tubes for this purpose towards the end of the century. During this period there were no adequate methods for assessing the safety of the vaccine and there were instances of contaminated vaccine transmitting infections such as erysipelas, tetanus, septicaemia and tuberculosis. In the case of arm-to-arm transfer there was also the risk of transmitting syphilis. Although this did occur occasionally, estimated as 750 cases in 100 million vaccinations, some critics of vaccination e.g. Charles Creighton believed that uncontaminated vaccine itself was a cause of syphilis. Smallpox vaccine was the only vaccine available during this period, and so the determined opposition to it initiated a number of vaccine controversies that spread to other vaccines and into the 21st century. Sydney Arthur Monckton Copeman, an English Government bacteriologist interested in smallpox vaccine, investigated the effects on the bacteria in it of various treatments, including glycerine. Glycerine was sometimes used simply as a diluent by some continental vaccine producers.
Sources: en.wikipedia.org
The East Prussian plebiscite (German: Volksabstimmung in Ostpreußen), also known as the Allenstein and Marienwerder plebiscite or Warmia, Masuria and Powiśle plebiscite (Polish: Plebiscyt na Warmii, Mazurach i Powiślu), was a plebiscite for the self-determination of the regions of southern Warmia (Ermland), Masuria (Mazury, Masuren) and Powiśle, which had been in parts of the East Prussian Government Region of Allenstein and of the West Prussian Government Region of Marienwerder in accordance with Articles 94 to 97 of the Treaty of Versailles. Prepared in early 1920, the plebiscite took place on 11 July 1920 and was conducted by German authorities under Inter-Allied control. The plebiscite reported that most voters had selected East Prussia over Poland (over 97% in the Allenstein Plebiscite Area and 92% in the Marienwerder Plebiscite Area). As a result, most of the territories in question remained in the Free State of Prussia and therefore in Germany.
=== Sweetpea Golightly === Sweetpea Golightly (Miriam Petche) is a new Pierpoint hire with TikTok and OnlyFans businesses on the side. She is revealed to have had an affair with Rishi, who subscribes to her OnlyFans page. Sweetpea is shown to be a shrewd and competent trader despite her seemingly carefree and social media-obsessed personality. She eventually discovers that a hefty debt Pierpoint issued five years ago to fund their pivot to ESG is reaching maturity, but cannot be paid off since the firm's ESG investments are not making any returns. She reports this to Eric, who tells her to keep it quiet; Harper later overhears Sweetpea telling Yasmin in the bathroom, and uses this information to plan a short of Pierpoint. After Pierpoint is sold to Al-Mi'raj Holdings, Sweetpea leaves the firm to go work for Harper. In series 4, Sweetpea works under Harper at Mostyn Asset Management, but is opposed to Harper's impulsive trading strategy. Sweetpea's explicit photos have leaked online, hurting her job prospects and straining her relationship with her mother. After Harper exits Mostyn's firm and starts her own fund with Eric called SternTao, she brings an apprehensive Sweetpea on board, and the two investigate the shady dealings of payment processing startup Tender, which Harper seeks to short. Sweetpea's investigation leads her on a trip to Accra alongside SternTao trader Kwabena Bannerman to uncover the truth behind Tender's business. Sweetpea is assaulted during the trip by a man possibly sent by Tender, and she and Kwabena have sex.
For example, the rare isotope carbon-14 was added to a particular tree and later detected in nearby plants and seedlings. One study observed a bidirectional carbon transfer between Betula papyrifera and Pseudotsuga menziesii, primarily through the hyphae of the ectomycorrhiza. However, not all plants are compatible with all fungal networks, so not all plants can exploit the benefits of established ectomycorrhizal linkages. The shared nutrient connection through CMNs has been suggested to be involved with other ecological processes such as seedling establishment, forest succession and other plant-plant interactions. Some arbuscular mycorrhizas have been shown to carry signals warning plants on the network of attack by insects or disease.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.